Displaying drugs 976 - 1000 of 15446 in total
Bepridil
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing...
Approved
Withdrawn
Matched Description: … It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. ... The drug produces significant coronary vasodilation and modest peripheral effects. …
Matched Categories: … Calcium-Regulating Hormones and Agents …
Matched Categories: … Calcium-Regulating Hormones and Agents …
Atoltivimab
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against ... INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020. ... attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Maftivimab
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against ... INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020. ... attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sulfaphenazole
Sulfaphenazole is a sulfonamide antibacterial.
Approved
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Nabilone
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as...
Approved
Investigational
Matched Description: … and emotional regulation. ... , and physiological effects. ... (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as …
Matched Categories: … Cannabinoids and similars ... Antiemetics and Antinauseants ... Alimentary Tract and Metabolism …
Matched Categories: … Cannabinoids and similars ... Antiemetics and Antinauseants ... Alimentary Tract and Metabolism …
Carbon monoxide
Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that has a slightly lower density than air. It is toxic to hemoglobin utilizing animals (including humans), when encountered in concentrations above about 35 ppm, although it is also formed in normal animal metabolism in low quantities, and is thought...
Approved
Investigational
Matched Description: … inflammatory diseases of the lung and other organs. ... The DLCO test is both convenient and simple for the patient to undergo. ... Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that has a slightly lower density than …
Brigatinib
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a...
Approved
Investigational
Matched Description: … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and ... Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Botulinum toxin type B
Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
Approved
Investigational
Matched Description: … and chromatography steps. ... The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin ... The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Tiaprofenic acid
Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the arylpropionic acid (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).
Approved
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Pralsetinib
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Rotigotine
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours....
Approved
Matched Description: … restless legs syndrome (RLS) in Europe and the United States. ... It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. ... (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and …
Amlexanox
Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of...
Approved
Investigational
Withdrawn
Matched Description: … Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and ... aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and …
Matched Categories: … Alimentary Tract and Metabolism …
Matched Categories: … Alimentary Tract and Metabolism …
Gliquidone
Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Approved
Investigational
Matched Description: … + influx, and eventually increases insulin release. ... This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2 …
Matched Categories: … Alimentary Tract and Metabolism …
Matched Categories: … Alimentary Tract and Metabolism …
Teicoplanin
Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine...
Approved
Investigational
Matched Description: … antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and ... All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Idarucizumab
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when...
Approved
Matched Description: … monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and ... Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Lorpiprazole
Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Matched Description: … Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive …
Axitinib
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … [L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. ... [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
Lumiracoxib
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling...
Approved
Investigational
Matched Description: … New Zealand and Canada have also followed suit in recalling the drug. …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Tyloxapol
Tyloxapol is a non-ionic detergent often used as a surfactant.
Approved
Investigational
Matched Categories: … Cough and Cold Preparations …
Homatropine
Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions. Homatropine is included in subtherapeutic amounts as homatropine...
Approved
Matched Description: … has been administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and ... the dilation of the pupil); however such therapeutic use has not been approved by the FDA to be safe and …
Matched Categories: … Mydriatics and Cycloplegics …
Matched Categories: … Mydriatics and Cycloplegics …
Abemaciclib
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Larotrectinib
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Description: … plays an important role in tumor cell growth and survival. ... receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and ... Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Tovorafenib
Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational
Matched Description: … growth and survival. ... [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell ... [L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation …
Idelalisib
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Description: … (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils ... signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and ... type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pegaptanib
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Pegaptanib was granted FDA approval on 17 September 2004.
Approved
Investigational
Matched Description: … neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Displaying drugs 976 - 1000 of 15446 in total